Skip to main content
. 2020 Mar 13;9(10):3328–3336. doi: 10.1002/cam4.2984

FIGURE 1.

FIGURE 1

Kaplan‐Meier curves of progression‐free survival (PFS) with crizotinib treatment and platinum‐based chemotherapy in ROS1‐positive advanced non‐small cell lung cancer. The median PFS was significantly longer in patients treated with crizotinib compared with those treated with platinum‐based therapy (median 14.9 mo vs 8.5 mo, respectively; P < .001)